Quote from emmadosending on August 28, 2025, 6:06 amBuy Raloxifene is a selective estrogen receptor modulator (SERM) primarily used for osteoporosis treatment and breast cancer prevention in postmenopausal women at high risk. While it has shown significant effectiveness in reducing the risk of invasive estrogen receptor-positive (ER+) breast cancer, it is not commonly used as a primary treatment for breast cancer. Instead, medications like tamoxifen or aromatase inhibitors are more widely prescribed for active breast cancer management.
Raloxifene works by blocking estrogen’s effects in breast tissue while mimicking its beneficial actions in bones, making it valuable for women concerned about both cancer risk and osteoporosis. Clinical trials, such as the STAR (Study of Tamoxifen and Raloxifene) trial, demonstrated that raloxifene is nearly as effective as tamoxifen in lowering breast cancer risk, but with fewer risks of uterine cancer and blood clots.
However, raloxifene is approved for prevention, not treatment, of breast cancer. Its role is primarily in women who have not yet developed the disease but are considered high-risk due to family history or other factors. For patients already diagnosed with breast cancer, oncologists typically recommend other hormone therapies better suited to treat active disease. Thus, raloxifene remains a preventive option rather than a therapeutic one.
Buy Raloxifene is a selective estrogen receptor modulator (SERM) primarily used for osteoporosis treatment and breast cancer prevention in postmenopausal women at high risk. While it has shown significant effectiveness in reducing the risk of invasive estrogen receptor-positive (ER+) breast cancer, it is not commonly used as a primary treatment for breast cancer. Instead, medications like tamoxifen or aromatase inhibitors are more widely prescribed for active breast cancer management.
Raloxifene works by blocking estrogen’s effects in breast tissue while mimicking its beneficial actions in bones, making it valuable for women concerned about both cancer risk and osteoporosis. Clinical trials, such as the STAR (Study of Tamoxifen and Raloxifene) trial, demonstrated that raloxifene is nearly as effective as tamoxifen in lowering breast cancer risk, but with fewer risks of uterine cancer and blood clots.
However, raloxifene is approved for prevention, not treatment, of breast cancer. Its role is primarily in women who have not yet developed the disease but are considered high-risk due to family history or other factors. For patients already diagnosed with breast cancer, oncologists typically recommend other hormone therapies better suited to treat active disease. Thus, raloxifene remains a preventive option rather than a therapeutic one.
